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Introduction
Conclusion
Experimental Protocol: Capillary Device
• Processing of human cells at large scale
demands an understanding of the effects
of the engineering environment on cell
quality.
•The ability to work with small quantities
of cells at an early stage of development
and predict the effect of the engineering
environment will greatly speed the design
of large scale operations.
•An array of engineering and biological
tests were performed to understand how
processing parameters could affect
product quality.
•Two cell lines, OnyCap23 and P4E6,
which are part of a multi-cell prostate
cancer vaccine were tested in this study.
•An experimental methodology has been
developed in order to study the impact of the
hydrodynamic environment upon several
biological characteristics of two cell lines.
•P4E6 cell line was shown to be more resistant
to the hydrodynamic stress for all the critical
quality attributes measured.
•Future work aims to move this technology to an
automated platform in order to study the
relationship of the critical elongational stress
values with process stages such as pumping,
vialling, etc.
•An ultra scale-down approach using capillary
shear devices allowed the rapid characterization
of human cell lines in terms of their resistance
to hydrodynamic stress. To understand the cell
response to hydrodynamic stress critical quality
attributes like cell membrane integrity, cell size
and surface phenotype were measured.
Process Flow Sheet
•Cells suffer different types of
hydrodynamic stresses according to
specific unit operations.
•The engineering environment will define
product quality. In the case of whole cell
cancer vaccines, the material is presented to
the patient’s immune system.
•The correlation between process limits and
the properties of individual cell lines will
define equipment selection and optimal
operating strategies.
•This study focuses mainly on the stress
suffered during re-suspension, formulation,
vialling and injection.
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OnyCap23
•Computational fluid dynamics were used to
analyze the capillary entry region to allow the
properties of the cells to be characterized in terms
of a critical stress below which there is no
significant loss of membrane integrity or
characteristic surface markers.
•The results suggested that the OnyCap23 and
P4E6 cell lines are resistant to damage below
critical elongational shear stress values of 235
N/m2 and 275 N/m2 respectively.
•The effect of capillary shear on the cell surface
markers was also measured by flow cytometry.
•Mean fluorescent intensity results suggest that
after one pass, capillary shear has a negative














•A biopotency co-culture assay showed an up-
regulation of INFγ release by immune cells in
response to sheared cells.
•A Luminex cytokine multiplex assay showed an
increase of IL-6 and IL-8 concentrations for both
cell lines after shear. These cytokines are














•A DoE approach was used to study the effect of
multiple process inputs on the final cell integrity.
The relative sensitivity observed for the three
variables studied was: flow rate 1.0, number of
passes 0.26 and capillary length 0.08.
P4E6
•The effect of capillary shear on the cell size was
measured using an automated image analysis tool.
•After one pass at high shear rates it is possible to
see an increase in the average size of the cell
population and a reduction in the total cell number
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•The production process of
whole cell therapies starts with
cell growth, either adherent or
suspension.
